Working Group on New TB Drugs

06/27/2019

Spero Therapeutics announces collaboration with Bill & Melinda Gates Medical Research Institute to develop SPR720 for treatment

CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and....

06/07/2019

U.S. Food and Drug Administration's Antimicrobial Drug Advisory Committee voted 14-4 in favor of TB Alliance - Community Engagement's new chemical entity when used in combination with and for & TI,NR-MDR

The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new chemical entity, pretomanid, in combination with bedaquiline and linezolid in an all-oral 6-month defined regimen f...

06/06/2019

The US FDA will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new chemical entity, pretomanid, in combination with bedaquiline and linezolid in an all-oral 6-month defined regimen for adults with extensively drug resistant (XDR) tuberculosis or treatment-intolerant or non-responsive multidrug resistant (MDR) tuberculosis.

The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new chemical entity, pretomanid, in combination with bedaquiline and linezolid in an all-oral 6-month defined regimen f...

03/13/2019

TB Alliance announces review of for use against Tuberculosis http://ow.ly/RB9030o21KQ

10/09/2018

Treatment Action Group released an updated guide on Bedaquiline summarizing updated efficacy, safety, and access information. The drug is essential for treating MDR-TB and recommended by WHO. Access the full guide here:

10/09/2018

Download the new guide to with recommendations on treating courtesy of Treatment Action Group

This guide — updated from the original version put out by Treatment Action Group in 2013 — summarizes updated efficacy, safety, and access information about bedaquiline, an essential medication in the treatment of multidrug-resistant TB (MDR-TB). We wrote this guide to provide information about ...

09/26/2018

RT : Every country should drastically increase investment to US$2 billion/year to close funding gaps for TB R&D needed to eliminate TB as a public health threat
Watch the at NOW! http://webtv.un.org http://pic.twitter.com/yWy1Z47hGU

09/26/2018

RT : Read our CEO Mel Spigelman's interview with : "The world cannot eliminate TB without commitments not only from high income countries, but from all TB endemic countries."

http://economictimes.indiatimes.com/industry/healt…

09/25/2018

The challenge is a major topic of discussion during the . :drug-resistant TB, a major part of , poses a serious threat to said by experts in 1st episode of buff.ly/2KV1Uxh

09/19/2018

The WHO released their Global TB Report this week, which indicated that 10 million people developed TB in 2017 and MDR-TB cases increased compared to last year. Right now, we’re not investing the money needed to end TB. There is an existing gap of 3 billion dollars between the financing needed to fight the epidemic (including funds for research & development) and the funds that are actually available. The UN high-level meeting on tuberculosis taking place next week provides a historical opportunity to mobilize national and international commitments and take decisive action to end TB and even more importantly drug-resistant TB.

The World Health Organization released its annual Global Tuberculosis report on September 18th. The report is 250 pages long, a massive conglomeration of everything we know about the current state of the Tuberculosis (TB) epidemic. It has all the newest data on TB infections, funding approaches, res...

09/18/2018

TB is the world's deadliest infectious disease, but the much needed TB innovation remains stagnant due to obstacles encountered by bringing products to market. It is critical for the TB and global health community to work together with innovators to actively remove the barriers they face. Read more here:

People think TB belongs in the pages of a Dickens novel, but it is the world's deadliest infections disease.

08/14/2018

New WGND Podcast "The Dose" Premieres Today. Listen to Episode 1 "TB and the AMR Crisis"

The Stop TB Partnership's Working Group on New Drugs presents a new podcast series entitled "The Dose". In this series, the WGND will bring together drug developers, researchers in the TB R&D field, TB patients, global health experts, and donors to discuss, prioritize, and develop strategies to help...